Systems and methods for diagnosing and treating nasal conditions using tissue biomarkers

A method for treating tissue, the method comprising:

• assessing one or more biomarker profiles in nasal tissue, the one or more biomarker profiles being indicative of rhinitis;
• providing an initial treatment, based on the assessed biomarker profiles, to one or more target tissue areas in a nasal cavity by activating one or more energy delivery elements positioned on a treatment element of a treatment device;
• monitoring the one or more biomarker profiles during the initial treatment to track the initial treatment provided with the one or more energy delivery elements of the treatment device;
• and
• providing additional treatment, based on the monitored biomarker profiles during the initial treatment, to the one or more target tissue areas in a nasal cavity,
• wherein the one or more biomarker profiles relate to tyrosine hydroxylase (TH), choline acetyltransferase (ChAT), neuropeptide Y (NPY), calcitonin gene-related peptide (CGRP), neurokinin A (NKA), neurokinin B (NKB), or substance-P (SP).

A method for treating tissue, the method comprising:

• assessing a first set of biomarker profiles in nasal tissue, the first set of biomarker profiles being indicative of rhinitis;
• providing treatment by applying energy to one or more target tissue areas in a nasal cavity with one or more pairs of electrodes;
• assessing a second set of biomarker profiles in nasal tissue after providing the treatment to the one or more target tissue areas;
• and
• comparing the first set of biomarker profiles to the second set of biomarker profiles to monitor the treatment to determine success of the treatment in treating rhinitis,
• wherein the biomarker profiles relate to tyrosine hydroxylase (TH), choline acetyltransferase (ChAT), neuropeptide Y (NPY), calcitonin gene-related peptide (CGRP), neurokinin A (NKA), neurokinin B (NKB), or substance-P (SP).